Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions By Angus Liu Jun 26, 2025 10:55am Vor Biopharma RemeGen Autoimmune Diseases Licensing deals ...

Telitacicept could generate $1.8 billion in U.S. sales if it captures 15% of the gMG market at $225K per patient. Vor will pay $125 million upfront to RemeGen, with milestone payments exceeding $4 ...

The deal signals an abrupt turnaround for Vor Bio. Once an incumbent in the cell and gene therapy space, the company became a casualty of the sector’s poor performance. The biotech wound down ...

Vor Bio (NASDAQ:VOR) stock soars 100% with a $175M funding boost and a major autoimmune therapy licensing deal. Read more here.

Shares of Vor Bio are up 120% in pre-market trade on Thursday. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do ...

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4) GlobeNewswire Jul 1, 2025, 8:00:00 PM Vor Bio Announces $175 Million Private Placement GlobeNewswire Jun 25, 2025, 8:50:16 PM ...

Pharma Fierce Pharma Asia—Vor-RemeGen, Otsuka-Harbour autoimmune deals; Datroway's lung cancer nod By Angus Liu Jun 27, 2025 8:37am Fierce Pharma Asia RemeGen Otsuka Daiichi Sankyo ...

London Borough of Tower Hamlets Council is aiming to eliminate unexpected vehicle off road (VOR) issues after adopting new fleet management software. The local authority, which operates 350 ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, Massachusetts ...